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INTRODUCTION
Human hepatitis B virus (HBV), which is the prototype 
member of  the family Hepadnaviridae, is a circular, 
partially double-stranded DNA virus of  approximately 
3200 nt[1]. This highly compact genome contains the four 
major open reading frames encoding the envelope (preS1, 
preS2 and surface antigen HBsAg), polymerase (HBPol) 
and X (HBX) proteins, respectively[2]. HBV is an etiologic 
agent of  acute and chronic liver disease, including fatal 
fulminant hepatitis, liver cirrhosis and hepatocellular 
carcinoma[3-6]. Over 2 billion people worldwide have been 
exposed to HBV and 350 million are chronic carriers of  
HBV[7-9].
In 1988, HBV was classified into four genotypes by a 
sequence divergence in the entire genome exceeding 8%, 
and designated by capital letters of  the alphabet from A 
to D[10,11]. In 1994, Norder et al[12] found an additional two 
HBV genotypes by the same criteria, and named them E 
and F, respectively. Genotype G was reported recently in 
2000[2] and genotype H, which is phylogenetically closely 
related to genotype F, was proposed in 2002[11]. HBV 
genotypes have distinct geographical distribution[2,7,13,14].
In general , genotype A is pandemic, but most 
prevalent in North West Europe, North America, Central 
Africa[2,13] and India[7]. Genotypes B and C are prevalent 
in Asia[7,8,13,15], especially in populations of  Eastern Asia 
and the far East origin[3,16]. Genotype D is also more or 
less pandemic, but is predominant in the Mediterranean 
area and the Middle East[2,3,16]. Genotype E is restricted 
to Africa and genotype F is found in Central and South 
America[7,8,13,16]. Genotype G has been recently identified 
in France and North America[7,8]. It has been reported 
that there are remarkable differences in the clinical and 
virologic characteristics between the patients with different 
genotypes[17,18,19]. According to Iranian studies[20], over 35% 
of  Iranians have been exposed to HBV, approximately 2% 
are chronic carriers. Compared to the United States where 
HBV infection is responsible for 25% of  chronic hepatitis, 
HBV accounts for up to 70%-80% of  chronic hepatitis 
cases in Iran, indicating that HBV alone is the leading 
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Abstract
AIM: To determine the prevalence of hepatitis B virus 
(HBV) genotypes in Iranian hepatitis B surface antigen 
(HBsAg) carriers, chronic hepatitis B and cirrhotic 
patients.
METHODS: A total of 109 HBsAg-positive patients were 
included in this study. HBV genotypes were determined 
by using INNO-LiPA methodology which is based on the 
reverse hybridization principle. 
RESULTS: The distribution of patients with different 
stages of liver disease was as follows: 95 (86.4%) 
chronic hepatitis, 11 (10%) liver cirrhosis, and 3 (2.7%) 
inactive carrier. Of the chronic hepatitis and liver cirrhosis 
patients, 26.4% were HBeAg-positive while 70% were 
HBeAg-negative. Genotype D was the only detected type 
found in all patients.
CONCLUSION: Classifying HBV into genotypes has to be 
cost-effective and clinically relevant. Our study indicates 
that HBV genotype D prevails in the Mediterranean area, 
Near and Middle East, and South Asia. Continued efforts 
for understanding HBV genotype through international 
co-operation will reveal further virological differences of 
the genotypes and their clinical relevance.
© 2006 The WJG Press. All rights reserved.
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cause of  chronic liver disease in Iran[21]. Until now, to our 
knowledge, no data regarding HBV genotype is available, 
and also the genotypes distribution of  HBV and genotype-
related differences with the liver disease are still unclear in 
Iran. In this study, we therefore determined the prevalence 
of  HBV genotypes in Iranian hepatitis B surface antigen 
(HBsAg) carriers, chronic hepatitis B and cirrhotic patients.
MATERIALS AND METHODS
This cross-sectional study was performed in Tehran 
Hepatitis Center in 2004. A total of  109 patients with 
hepatitis B surface antigen (HBsAg) positive for at least 
6 mo were enrolled in this study. Of  the 109 patients, 95 
were classified as chronic hepatitis, defined as HBsAg 
positivite with or without the presence of  HBeAg, high 
level of  HBV-DNA (> 100 000 copies/mL) detected 
by Amplicor HBV monitor, persistent or intermittent 
elevation in ALT levels and compatible liver biopsy. 
Three were inactive carriers characterized by persistent 
HBV infection of  liver without significant, ongoing 
necro-inflammatory disease. Eleven had liver cirrhosis 
characterized by clinical evidence (splenomegaly, ascitis) 
and paraclinical results, including low platelet count, 
prolongation of  prothrombin time and esophageal varices 
on upper gastrointestinal endoscopy. Liver cirrhosis was 
confirmed by liver biopsy. Patients were excluded if  they 
were co-infected with hepatitis C virus (HCV), hepatitis D 
virus (HDV) or human immunodeficiency virus (HIV).
The following parameters were recorded for each 
patient from patient’s document in Tehran Hepatitis 
Center: sex, age, stage of  liver disease, alanine amino-
transferase (ALT) level, aspartate transaminase (AST) and 
presence of  hepatitis B virus E antigen and anti-hepatitis 
B virus E antibodies. 
HBV genotypes were determined by using INNO-LiPA 
methodology (LiPA, INNO-LiPA HBV genotyping assay, 
Innogenetics N.V., Ghent, Belgium). The INNO-LiPA 
HBV genotyping assay is a line probe assay designated to 
identify hepatitis B virus genotypes A to G by detection 
of  type-specific sequences in the HBV-pol gene domain 
B to C. This method is based on the reverse hybridization 
principle. Biotinylated DNA material generated from the 
HBsAg open reading frame was hybridized with specific 
oligonucleotide probes immobilized as parallel lines on 
membrane-based strips. After hybridization, unhybridized 
DNA was washed from the strip, alkaline phosphatase-
labeled streptavidin was added and bounded to any 
biotinylated hybrid previously formed. Incubation with 
BCIP/NBT chromogen resulted in a purple/brown 
precipitate. Amplification of  appropriate the HBV 
genomic region was performed using the INNO-LiPA 
HBV DR amplification kit. The INNO-LiPA HBV 
genotyping strip contains 1 red marker line, 2 control lines, 
and 14 parallel probe lines. The conjugate control line 
is a control for the color development reaction and the 
amplification control line contains universal HBV probes 
to check for the presence of  amplified the HBV genomic 
material.
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Statistical analysis
Data were analyzed with SPSS 11.5 software (SPSS Inc. 
Chicago, Illions, USA) using Student’s t test, χ2 test and 
Fisher’s exact test.
RESULTS
A total of  109 patients with a mean age of  37.17 ± 
11.75 years, including 13% females and 87% males, were 
enrolled in this HBV genotype study. The distribution of  
patients in different stages of  liver disease was as follows: 
95 (86.4%) chronic hepatitis, 11 (10%) liver cirrhosis, 
and 3 (2.7%) inactive carrier. Of  the chronic hepatitis 
and liver cirrhosis patients, 26.4% were HBeAg-positive 
and 70% were HBeAg-negative. The mean serum ALT, 
AST, and ALP levels were 126.08 IU/L (88.46-163.71), 
86.46 IU/L (49.54-123.39), 173.34 IU/L (152.74-193.94), 
respectively.
Genotype D was the only detected type found in all 
patients. Mean age of  patients was significantly higher in 
the anti-HBe-positive group as compared with the HBe-
Ag-positive group (P = 0.000). Also, the number of  the 
patients in the anti-HBe-positive group was significantly 
higher than the HBe-Ag-positive group (P = 0.019; Fisher’
s exact test). Moreover, significant difference was found 
between the mean age of  patients with different stages of  
liver disease. None of  the patients in the HBe-Ag-positive 
group had a normal ALT level. Most of  the patients in 
the chronic hepatitis stage had an abnormal ALT level 
in comparison with the liver cirrhosis stage (P = 0.024; 
Fisher’s exact test).
DISCUSSION
Classifying HBV into genotypes has to be cost-effective 
and clinically relevant. It is imperative to collect more 
information on HBV genotypes from all over the world to 
reach a decision on their clinical utility[11].
Data on the relation among the HBV genotypes, 
their pathogenicity in chronic liver disease including 
hepatocellular carcinoma and their effect on therapy are 
awaited with great interest, especially in Asia which is an 
endemic region of  blood-borne hepatitis viruses[15].
Presently, based on an intergroup divergence of  8% or 
more in the complete nucleotide sequence, HBV can be 
classified into eight genotypes A-H, and different HBV 
genotypes are dominant in various parts of  the world[14,16]. 
The most important finding of  our study was that the 
only HBV genotype D was detected in all patients. The 
pattern of  distribution of  genotypes seemed to be simpler 
and was predominantly centralized into genotype D in 
all forms of  the chronic HBV infection. The results of  
this study concur with previous studies, indicating that 
HBV genotype D prevails in the Mediterranean area, Near 
and Middle East, and South Asia[3,4,16]. For example, the 
result of  a similar study performed in Turkey showed all 
44 patients studied had genotype D[16]. Another study in 
Yemen demonstrated that genotype D was the dominant 
genotype in a settled population, while genotype A was 
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found only in communities with continuing African 
l inks [22]. In addit ion, one study in Egypt revealed 
genotype D was the most prevalent HBV genotype[23]. 
On the contrary, genotypes A, B and C were found to be 
predominant in Pakistan[24]. According to recent studies, 
genotype D in Asia is associated with more severe disease 
and may predict occurrence of  hepatocellular carcinoma in 
younger patients[9].
After all, only less than 1 000 of  the 350 million 
persistent HBV infections have yet been genotyped. 
Continued efforts for understanding HBV genotypes 
through international co-operation will reveal further 
virological differences of  the genotypes and their clinical 
relevance.    
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